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Background/aim: Management of atopic dermatitis (AD) in children is still challenging. The aim of this study was to evaluate the
efficacy and safety profile of cyclosporine-A (CsA) treatment in children with severe and recalcitrant AD.
Materials and methods: Medical records of 43 children followed between January 2010 and December 2015 and treated with systemic
CsA were evaluated retrospectively. Treatment efficacy was assessed according to the physician’s global assessment (PGA) score.
According to the treatment response, patients were grouped as nonresponder, moderate responder, or good responder. Effects of the
variables on treatment response were evaluated by analysis of variance (ANOVA). The safety profile of CsA was assessed by clinical and
laboratory findings at each visit.
Results: The median initial dose of CsA was 3 mg/kg daily, ranging between 2.5 and 5 mg/kg daily. The mean duration of CsA therapy
was 4.9 ± 4.24 months. Seventeen patients (39.5%) achieved good response in a treatment period of 3 to 14 months. After discontinuation
of CsA, of the 17 patients, relapse was observed in 4 (23.5%). Moderate response was observed in 12 (27.9%) patients; however, 14 (32.6)
patients did not respond to the treatment. Five patients reported mild side effects.
Conclusion: Low-dose CsA seems to be an effective and safe treatment option for severe and recalcitrant AD in children.
Key words: Atopic dermatitis, cyclosporine-A, treatment

1. Introduction
Atopic dermatitis (AD) is a T cell-mediated chronic
inflammatory skin disease characterized by relapsing
pruritic skin lesions that mostly presents in early childhood
with an estimated prevalence of 15%–30% in children and
2%–10% in adults (1). Atopic dermatitis is characterized
by the complex interaction between multifactorial
abnormalities including defects in epidermal barriers,
immune dysregulation, and polymorphisms like filaggrin
gene mutation. Furthermore, environmental factors have
been implicated in the pathogenesis (2,3).
On account of the chronicity of AD, which is mostly
seen in childhood, management of AD is still a therapeutic
challenge. Restoration of the skin barrier, avoidance of
triggers, and reduction of inflammation are aims for the
management of AD. Concerning the side effects of systemic
therapies in growing children, the majority of patients
can be treated effectively with topical agents including
emollients, topical corticosteroids, and calcineurin
inhibitors or phototherapy with various response rates.
However, systemic therapy is required especially in severe

and recalcitrant AD, defined as unresponsiveness to
conventional topical therapies and phototherapy (4).
Cyclosporine-A (CsA) is an immunosuppressive
agent that inhibits calcineurin and blocks T-lymphocyte
activation. It has been reported that systemic CsA therapy
is as effective and safe in pediatric patients with psoriasis
as it is in adults (5). Even though CsA is approved in
Europe as a first-line systemic treatment for severe AD in
children and adults, data on its efficacy and safety profile
in childhood population are scarce (6).
The aim of this study was to evaluate the efficacy and
safety profile of CsA treatment in children with severe and
recalcitrant AD retrospectively.
2. Materials and methods
2.1. Patients
Medical records of 43 patients with severe and recalcitrant
AD who were under 18 years of age (6–17 years of age) and
treated with systemic CsA were retrospectively evaluated.
All patients, followed at the tertiary care reference center
between January 2010 and December 2015, were admitted
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or referred to us due to severe disease and recalcitrance
to conventional therapies. Severe and recalcitrant AD
is defined clinically as chronic disease resistant to
conventional and adjunctive therapies (6). Patients who did
not fulfill the criteria of Hanifin and Rajka were excluded.
Patients’ clinic characteristics and demographic features,
including age of the patient at the onset of CsA treatment,
sex, localization of the lesions, personal and/or family
history of atopy, duration of disease, previous therapies
and therapeutic parameters of CsA treatment including
dosage, duration of therapy, response to therapy, total
IgE levels, clinical and laboratory side effects, and followup period, were retrieved from medical records. Ethics
approval was obtained from the local ethics committee.
2.2. Cyclosporine-A therapy
In accordance with the current literature, disease severity
and recalcitrance to conventional therapies (topical
steroids, topical calcineurin inhibitors, and phototherapy)
were the indications for systemic CsA therapy in patients
with AD in our clinic. Written informed parental consent
regarding contraindications of CsA, which are uncontrolled
infection, malignancy or history of malignancy, abnormal
renal or liver function and hypertension, and unauthorized
concomitant medication, was obtained. CsA was supplied
as capsules containing 25, 50, or 100 mg. Children unable
to swallow the capsules were treated with an oral solution
containing 100 mg/mL. The initial dose of CsA was
between 2.5 to 5 mg/kg daily, given twice daily. The dosage
was maintained until the patient substantially improved. In
patients with controlled AD, defined as relief of symptoms
as mentioned by the patient, and satisfactory results as
reported by the physician, the CsA dose was gradually
tapered by 0.5 to 1 mg/kg daily every 2 to 4 weeks according
to the therapeutic response. After the initiation of CsA
therapy, patients were followed closely with examinations
every 2 weeks for the first month and thereafter once a
month as suggested (5). All clinical and laboratory side
effects were assessed at each visit. Concomitant emollients
and topical therapies were permitted during CsA therapy
as reported in previous reports (1,10–16). Emollients and
topical steroids were permitted during CsA therapy. In
patients who had been given phototherapy, CsA therapy
was started after a washout period of at least 6 weeks.
2.3. Side effects
Side effects were assessed at each visit. The assessment of
side effects included physical examination, blood pressure
measurement, full blood count, serum urea, creatinine,
electrolytes, magnesium, cholesterol and triglycerides
levels, and urine osmolarity. Any complaints that were
considered to be a clinical adverse effect of CsA were
also reported. Serum creatinine levels and blood pressure
(BP) were assessed at baseline and at each visit during the
follow-up period of therapy. According to our treatment
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protocol, the CsA dose was reduced or treatment was
discontinued if serum creatinine levels were elevated
more than 30% above the patient’s baseline level on two
consecutive occasions, even if the serum creatinine level
was still within the normal range as recommended.
2.4. Assessment of treatment response
Treatment efficacy was evaluated retrospectively from the
medical records of the patients according to the physician’s
global assessment (PGA) scores. Seeing that multiitem
scales are not routinely used in daily clinical practice, we
applied a global assessment on an ordinal scale to measure
the clinical response. The PGA is an overall assessment
from 0 to 5 of a patient’s eczema, evaluating the quality and
extent of the lesions relative to the baseline assessment (0 =
clear (100%), 1 = almost clear (90% to 99% improvement),
2 = marked improvement (50% to 89%), 3 = modest
improvement (<50%), 4 = no change, and 5 = worse).
Treatment response was grouped as good response:
patients successfully treated (PGA score of 0–2); moderate
response: patients with moderate improvement (PGA
score of 3); or failure of treatment: no improvement (PGA
score of 4–5). Controlled AD was defined as relief of AD
symptoms as mentioned by the patient and a satisfactory
result as reported by the physician (7).
2.5. Follow-up after discontinuation of cyclosporine-A
treatment
In the good to moderate outcome groups, we considered
disease to be in clinical remission when the disease was
cleared away or could be controlled with topical therapy
(moderately potent steroids) and improvement lasted
at least 3 months. After discontinuation of CsA therapy,
relapse was declared if an exacerbation of clinical
symptoms at baseline severity occurred within 3 months,
and rebound was declared if an exacerbation of eczema
more severe than that at baseline occurred.
2.6. Statistical analysis
SPSS 20.0 for Windows (IBM Corp., Armonk, NY,
USA) was used for the statistical analysis. Data were
summarized and organized in tables. They were analyzed
by using descriptive statistics, given as mean ± standard
deviation (SD), median, range (minimum–maximum),
and percentage. Effects of variables on treatment response
including presence of family history of atopy, duration of
disease, initial dose, and duration of CsA therapy were
evaluated by analysis of variance (ANOVA). P < 0.05 was
considered statistically significant.
3. Results
3.1. Demographic features
A total of 43 children were treated with systemic CsA
(capsule or oral solution) with the diagnosis of severe and
recalcitrant atopic dermatitis. Of the patients, 24 were
male and 19 were female. The age of the patients during
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CsA treatment ranged from 6 to 17 years (mean: 10.94 ±
4.48 years). A positive family history of atopy was found
in 10 (23%) patients. The median total IgE level was 336.5
(21.2–6126.0) kU/L. All patients had been previously
treated with emollients, topical corticosteroids, and topical
calcineurin inhibitors, and 8 of them were treated with
phototherapy (7 with narrow-band UVB and 1 with UVA1). The demographic and clinical features of the patients
are summarized in Table 1. Baseline BP measurement,
serum creatinine, urinalysis, complete blood cell count,
and renal and liver function tests were all within normal
limits in all patients. None of the patients had a history of
an infectious disease as a trigger.
3.2. Therapeutic parameters of cyclosporine-A
The median initial dose of CsA was 3 mg/kg daily (range:
2.5–5). The mean duration of CsA therapy was 4.9 ± 4.24
months. The therapeutic parameters are presented in Table
1. Seventeen patients (39.5%) achieved good response in
a treatment period that varied between 3 and 14 months.
Fourteen patients who did not respond to CsA were treated
for 3 months or less. Treatment duration varied between 3
and 18 months with a mean of 7.01 ± 3.96 months and
the median was 6 months in patients with moderate
to good response. The mean duration of the disease
was 2.71 months, 7.25 months, and 6.18 months in the
nonresponder, moderate responder, and good responder
groups, respectively. Moreover, the mean duration of CsA
therapy was 2.64 months in the nonresponder group, but
4.33 months in moderate responders and 7.44 months in
good responders. The associations between the duration
of treatment and the treatment response (P = 0.04) and
the duration of disease and the treatment response (P =
0.046) were statistically significant and may be attributable
to the small sample size. There was no other statistically
significant difference regarding criteria including family
history of atopy, initial dose of CsA therapy, age at the
onset of disease, sex, and total IgE levels between good,
moderate, and nonresponder groups.
3.3. Follow-up
Four of the 17 patients who were in the good responders
group relapsed. One of them relapsed within a month and
2 within a year after discontinuation of CsA therapy. The
other patient was lost to follow-up. We did not find any
statistically significant difference regarding the duration
of the disease, duration of the treatment, and dose of CsA
between relapsed and nonrelapsed groups. Two of 14
patients who did not respond to CsA,were given CsA (3–4
mg/kg daily) again for 3 months with moderate response.
In the nonresponder group, CsA therapy was stopped due
to nonadherence to treatment in 3 patients. In the other
patients who were unresponsive to CsA therapy, CsA was
switched to systemic steroid or methotrexate therapy with
variable response rates. Five patients (11.6%) reported

Table 1. Demographic and clinical features of the patients and
cyclosporine-A (CsA) therapeutic parameters.
n

43

Sex, n (%)
Male
Female

24 (55.8%)
19 (44.2%)

Age at onset of CsA therapy, years
Mean ± SD

10.94 ± 4.48

Median; min–max

12; 6–17

Lesion localizations, n (%)
Flexural

8 (18.6%)

Trunk and extremities

25 (58.1%)

Generalized

10 (23.3%)

Duration of disease, years
Mean ± SD

5.34 ± 5.03

Median; min–max

3.0; 1-17

IgE levels (kU/L)
Mean ± SD

965.9 ± 1483.8

Median; min–max

336.5; 21.2–6126.0

Family history of atopy, n (%)

10 (23.3%)

Initial dose of CsA therapy, mg/kg daily
Mean ± SD

3.26 ± 0.76

Median; min–max

3; 2.5–5

Duration of CsA therapy, months
Mean ± SD

4.9 ± 4.24

Median; min–max

4.0; 1.0–18.0

Response to therapy, n (%)
Good responder

17 (39.5%)

Moderate responder

12 (27.9%)

Nonresponder

14 (32.6%)

Follow-up (n = 17), n (%)
Complete remission

13 (76.5%)

Relapse

4 (23.5%)

Adverse effects, n (%)

5 (11.6%)

Dyspepsia

1 (2.3%)

Sore gums

2 (4.7%)

Hypertrichosis

1 (2.3%)

Flu-like symptoms

1 (2.3%)

SD, Standard deviation

mild to moderate tolerable side effects including dyspepsia,
hypertrichosis, sore gums, and flu-like symptoms. Renal
and/or hepatic dysfunction was not observed in any
patients.
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4. Discussion
Data on the efficacy and safety of CsA in the childhood
population are scarce. Therefore, CsA should only be
used in severe and recalcitrant cases and only if there is a
significant negative impact on the patient’s quality of life.

A review of the literature revealed a total of eight articles
including one of an open-label randomized controlled
trial regarding the use of CsA in pediatric patients with
AD with varied good remission rates, ranging between
11% and 95% (Table 2) (8–15). The initial dose of CsA has

Table 2. Review of articles on cyclosporine-A therapy for atopic dermatitis in children.
Author

Year

Study
design

Number Dosage,
Duration,
of cases, n mg/kg daily months

Response

Berth-Jones et
al. (8)

1996

OUC

27

5

1.5

Headache (7),
Complete remission
abdominal pain (6),
81.5%
nausea (4)

Zaki et al. (9)

1996

OUC

18

5–6

1–3

Good or very good
Nausea (1)
response 89%

Adverse effects

Harper et al. (10) 2000

Open-label
RCT

43

5

Rhinitis(19), infected
Good or very good
Continuous
eczema (15),
clinical response
(12mos) vs
bronchospasm (13),
intermittent (3 ≥75%
*URTI (13), headache
mos)
(9), folliculitis (1)

Bunikowski et al.
2001
(11)

OUC

10

2.5-5

2

Significant
improvement 90%

Mean 13.5

Hypertension (8),
renal dysfunction (1),
Prolonged remission
nausea and abdominal
95%
discomfort (3),
hypertrichosis (1)

Haws et al. (12)

2010

Retrospective
cohort

13

Mean 2.7

Elevated creatinine(1),
elevated bilirubin (1)

Sibbald et al. (13) 2015

Retrospective
cohort

15

Mean 2.8

Mean 10.9

Headache (1),
dyspepsia (1), eczema
Complete remission herpeticum (1), renal
dysfunction (1),
80%
pharyngitis (1), three
infections (1)

Beaumont et al.
(14)

Retrospective
cohort

35

5

5

Complete remission Eczema
(11%)
herpeticum (1)

2012

Hernandez2016
Martin et al. (15)

Retrospective
cohort

Present study

Retrospective
cohort

Current

63

43

Mean 4.27

Mean 3.26

Median 4.6

Good to excellent
response (64%)

Hypertrichosis (33),
gingival hypertrophy
(14), hyperazotemia
(5), headache (4),
muscle cramps (2),
elevated creatinine (1),
tremors (1)

Mean 4.9

Good responder
(39.5%)

Dyspepsia (1),
sore gums (2),
hypertrichosis (1), flulike symptoms (1)

OUC, Open uncontrolled; RCT, randomized controlled trial; *URTI, upper respiratory tract infections.
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been varied between 2 and 5–6 mg/kg daily. Two different
CsA doses have been used, low doses (2–3 mg/kg daily)
and high doses (5–6 mg/kg daily). It has been reported
that high doses achieve a faster response. Sibbald et al. (13)
suggested that longer duration of low-dose cyclosporine
may help decrease the risk of relapse. Our initial doses of
CsA (2.5–5 mg/kg daily) were similar to the doses used in
previous reports. We suggest that faster responses may be
achieved with higher doses of CsA.
The treatment duration is still inconclusive. A starting
dose of 5 mg/kg daily of CsA for a maximum of 6 months has
been traditionally recommended, but in the literature, two
different treatment regimens, which were multiple short
courses and continuous therapy, were compared. Harper
et al. (10) reported that almost 50% clinical remission
was observed in most patients who were given short-term
(multiple courses of 12 weeks) and 5 mg/kg daily of CsA.
Furthermore, the authors suggested that CsA is effective
for controlling severe AD in children over a 1-year period
and is well tolerated. The authors observed that a short
course of therapy was adequate for some patients, and also
reduced the cumulative exposure to the drug. Nonetheless,
they concluded that duration of treatment (mean duration
of therapy varied between 1.5 and 13.5 months) should
be tailored according to the patients’ needs (10). It is
noteworthy that the reports in which CsA was used for
less than 3 months were published before 2000 (8,9,11).
This may be explained by limited experience of CsA use
because of concern about potential side effects. Hijnen
et al. (7) reported that CsA was an effective treatment
option for recalcitrant cases with a dose of 2.5–5 mg/kg
daily with more than a 7-year safety profile. We observed
that 39.5% of the patients achieved good responses in a
period that varied up to 14 months. There are limited data
about variables impacting treatment response. Although
Hernandez-Martin et al. (15) reported that poor outcome
did not show a statistically significant association with
mean dosage or duration of therapy, we found statistically
significant associations of both duration of treatment and
duration of disease with treatment response (P = 0.04, P =
0.046, respectively). Increase in clinical response rates with
longer durations of CsA therapy indicates that long-term
therapy with lower CsA doses is an effective treatment
method in severe AD, compatible with the findings of Haws
et al. (12) and Sibbald et al. (13). Better clinical responses
in patients with longer duration of disease may predict
that higher doses of CsA are needed in the management
of acute severe disease. Although Bunikowski et al. (11)

reported that the therapeutic effect of low-dose CsA was
independent of the patients’ baseline clinical disease
severity, Hamid et al. (16) reported that acute AD skin
lesions expressed a higher number of inflammatory cells
than observed in chronic AD skin lesions. It is evident that
acute severe disease needs a more aggressive approach, as
in our observation.
Relapse was observed in 4/17 (24%) patients after
discontinuation of CsA, which was similar to what Hijnen
et al. (7) reported (34%). We realized that 14 patients who
did not respond to CsA were treated for 3 months or less.
Those cases being unresponsive may be ascribed to the
short course of treatment. Long remission after withdrawal
of treatment was seen in some patients, although most
relapsed within a few weeks.
It is proposed that children tolerate CsA better than
adults and the incidence of side effects is lower in children
(17). In our study, only five patients (11.6%) reported side
effects, which were tolerable. All side effects were similar to
those of previous reports and no serious organ toxicity was
observed. Haws et al. (12) reported that the development
of adverse events was related to a higher initial dose of
CsA. Only one patient discontinued therapy because of
reversible hypertrichosis.
Studies reported that the pharmacokinetics of CsA may
be different in children compared to adults, as children
generally have higher CsA clearance rates and absorption
of CsA is reduced in young children (18). According to the
literature, CsA is suggested to be an effective treatment for
pediatric patients with AD at the same dose that is used
in adult patients with psoriasis (5). In our experience and
also based on previous research, clinical improvement is
rapid and generally occurs within the first few weeks of
CsA therapy.
Our study has several limitations. Owing to the
retrospective nature of this study, available data for analysis
were limited. In addition, our sample size was small, and
the limited follow-up prevented us from making any
definite conclusions about the remission length and longterm safety of CsA treatment.
In conclusion, we suggest that low-dose CsA is an
effective and safe treatment option for children with
severe and recalcitrant AD. However, higher doses
may be required in acute and severe disease. Further
prospective and controlled studies with large sample sizes
are required to confirm and extend these findings and
recommendations for use of CsA in AD.
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